drugset
drugset / Trial / NCT06136364

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

NCT06136364 ↗

Phase 1 Recruiting 9 enrolled Hebei Senlang Biotechnology Inc., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.

Timeline

Start
2023-08-15
Primary completion
2024-08-15
Completion
2038-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject SENL101 Cell therapy — —

Indications

T-cell acute lymphoblastic leukemia T-lymphoblastic lymphoma